Frexalimab and progressive MS: what the early signals show and the open questions

# What was reported

A recent preclinical study (Tyystjärvi et al., Brain, 2026) found that an anti‑CD40L antibody reduced meningeal B‑cell aggregates and mitigated progressive autoimmune encephalomyelitis in an animal model. The MS‑Blog highlighted that frexalimab, a CD40‑ligand (CD154) blocking antibody, is being developed for both relapsing and progressive MS and that the new paper is being discussed as evidence it may affect progressive disease.

# What frexalimab targets

Frexalimab blocks the interaction between CD40 on B cells and CD40L on T cells. That interaction is a key part of T‑cell–B‑cell signaling, especially in memory B cells. Blocking CD40–CD40L can reduce the signaling that drives inflammation in immune‑mediated models.

# Why the animal result matters — and why it does not settle the question

The animal experiment showed fewer meningeal B‑cell aggregates and reduced progressive disease when CD40L was blocked. That is a concrete preclinical finding and helps explain why frexalimab is being tested in progressive MS.

The MS‑Blog emphasizes limits to extrapolation:

• The models used are primarily T‑cell driven. In those models, anti‑CD20 therapies often appear ineffective, which does not match the clinical behavior of anti‑CD20s in people. This difference reduces how directly animal outcomes translate to humans.

• The referenced preclinical study was reported outside direct pharmaceutical control, though some pharma employees contributed. Trial results, especially phase 3 pivotal trials now underway, will provide the decisive clinical evidence.

# Practical implications for patients and clinicians

The animal work supports the biological plausibility that disrupting CD40–CD40L signaling can change meningeal B‑cell pathology and disease course in that model. However, it does not prove frexalimab will slow progression in people. Ongoing clinical trials for relapsing and progressive MS will be necessary to determine safety and efficacy in patients.

Patient commentary reproduced on the blog described the drug as blocking T‑ and B‑cell signaling rather than killing cells, and noted that early trial participants are being randomized in blinded studies. This illustrates that people in trials may not know whether they receive the active drug or placebo while safety and efficacy are being evaluated.

# Bottom line

The preclinical finding is notable: anti‑CD40L reduced meningeal B‑cell aggregates and impeded progressive disease in an animal model. But key mechanistic and translational questions remain, especially about CNS access and differences between animal models and human MS. The results keep frexalimab high on the list of candidates to watch, but clinical trial outcomes will determine whether it can meaningfully affect progression in people with MS.